http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111500729-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate | 2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111500729-B |
| titleOfInvention | Application of plasma lnc-SCA7 in preparation of biomarker for judging whether patient is sensitive to neoadjuvant chemotherapy |
| abstract | The invention discloses application of plasma lnc-SCA7 in preparation of a biomarker for judging whether a patient is sensitive to neoadjuvant chemotherapy, and belongs to the technical field of biomedicine. The invention can distinguish patients sensitive to neoadjuvant chemotherapy from patients insensitive to neoadjuvant chemotherapy by determining the relative content of lnc-SCA7 in the plasma of the patients. |
| priorityDate | 2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 165.